Jefferies also prefers Concord Biotech over its peer Glenmark Life Sciences due to its superior growth profile, strong execution track record, industry-leading margins, and favourable return ratios.
Kotak Institutional Equities based on strong discounted cash flows and the company’s expertise in high entry barrier fermentation active pharmaceutical ingredients (API) segment sees a 15 percent upside potential from the current price levels.
Concord Biotech | The stock performance was much higher than analysts' expectations as well as grey market premium which was around 15 percent over the issue price.